Risk of breast cancer recurrence in patients receiving manual lymphatic drainage: a hospital-based cohort study.
CONCLUSION: MLD is a gentle procedure that does not increase the risk of breast cancer recurrence in patients who develop BCRL. PMID: 25767390 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 15, 2015 Category: Cancer & Oncology Authors: Hsiao PC, Liu JT, Lin CL, Chou W, Lu SR Tags: Ther Clin Risk Manag Source Type: research

K-core decomposition of a protein domain co-occurrence network reveals lower cancer mutation rates for interior cores.
CONCLUSION: Mutations and domain co-occurrence networks provide a framework for understanding hierarchal designs in protein function from a network perspective. This study provides evidence that a majority of protein domains in the inner core of the DCN have a lower mutation frequency and that protein domains present in the peripheral regions of the k-core contribute more heavily to the disease. These findings may contribute further to drug development. PMID: 25767694 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 15, 2015 Category: Cancer & Oncology Authors: Emerson AI, Andrews S, Ahmed I, Azis TK, Malek JA Tags: J Clin Bioinforma Source Type: research

CCR 20th Anniversary Commentary: BMS-247550-Microtubule Stabilization as Successful Targeted Therapy.
Abstract In a landmark article published in the May 1, 2001, issue of Clinical Cancer Research, Lee and colleagues reported the original preclinical studies demonstrating anticancer activity of BMS-247550 (ixabepilone) against taxane-sensitive and taxane-resistant cancers. Subsequent clinical trials established the clinical efficacy of ixabepilone, leading to its regulatory approval for the treatment of drug-resistant metastatic or locally advanced breast cancers. Clin Cancer Res; 21(6); 1237-9. ©2015 AACR. See related article by Lee et al., Clin Cancer Res 2001;7(5) May 2001;1429-37. PMID: 25770292 [Pub...
Source: Clinical Breast Cancer - March 15, 2015 Category: Cancer & Oncology Authors: Pabla N, Sparreboom A Tags: Clin Cancer Res Source Type: research

Correction: Silencing of Human Phosphatidylethanolamine-Binding Protein 4 Sensitizes Breast Cancer Cells to Tumor Necrosis Factor-α-Induced Apoptosis and Cell Growth Arrest.
Correction: Silencing of Human Phosphatidylethanolamine-Binding Protein 4 Sensitizes Breast Cancer Cells to Tumor Necrosis Factor-α-Induced Apoptosis and Cell Growth Arrest. Clin Cancer Res. 2015 Mar 15;21(6):1499-1501 Authors: PMID: 25770297 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 15, 2015 Category: Cancer & Oncology Tags: Clin Cancer Res Source Type: research

Correction: TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance.
Authors: PMID: 25770298 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 15, 2015 Category: Cancer & Oncology Tags: Clin Cancer Res Source Type: research

Role of physiotherapy and patient education in lymphedema control following breast cancer surgery.
CONCLUSION: Patient education that begins within the first week postsurgery and is followed by physiotherapy is effective in reducing the risk of BCRL in women with breast cancer. PMID: 25750536 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 13, 2015 Category: Cancer & Oncology Authors: Lu SR, Hong RB, Chou W, Hsiao PC Tags: Ther Clin Risk Manag Source Type: research

Genomic and non-genomic effects of glucocorticoids: implications for breast cancer.
Abstract Glucocorticoids (GC) are essential steroid hormones for human life. They regulate a series of important processes by binding with three glucocorticoid receptors (GR) and activating genomic and non-genomic pathways. Activated cytoplasmic GR can directly bind DNA and transactivate or transrepress specific genes. Additionally, it can interact with other transcription factors to affect gene expression indirectly. The two membrane GR can interact with mitogen-activated protein (MAP) kinases or activate cAMP and Ca(2+)-dependent pathways, respectively. Glucocorticoids have been widely used as co-treatment of pa...
Source: Clinical Breast Cancer - March 13, 2015 Category: Cancer & Oncology Authors: Mitre-Aguilar IB, Cabrera-Quintero AJ, Zentella-Dehesa A Tags: Int J Clin Exp Pathol Source Type: research

FOXA1 positively regulates gene expression by changing gene methylation status in human breast cancer MCF-7 cells.
CONCLUSIONS: FOXA1 may be associated with methylation of the tumor suppressor genes promoter through changing DNMTs expression. FOXA1 could be a potential demethylation target for prevention and treatment of breast cancer. PMID: 25755696 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 13, 2015 Category: Cancer & Oncology Authors: Zheng L, Qian B, Tian D, Tang T, Wan S, Wang L, Zhu L, Geng X Tags: Int J Clin Exp Pathol Source Type: research

MicroRNA-26a inhibits proliferation by targeting high mobility group AT-hook 1 in breast cancer.
Abstract OBJECTIVES: To investigate the crucial role of miR-26a in breast cancer and to validate whether miR-26a could regulate proliferation of breast cancer cells by targeting high mobility group AT-hook 1 (HMGA1). METHODS: Reverse transcription-polymerase chain reaction (RT-PCR) was used to quantify the expression levels of miR-26a in breast cancer and adjacent non-cancerous breast tissues. MTT, cell migration and invasion assay were carried out to characterize the miR-26a function. Finally, to validate the target gene of miR-26a, luciferase reporter assay was employed, followed by RT-PCR and Western blot ...
Source: Clinical Breast Cancer - March 13, 2015 Category: Cancer & Oncology Authors: Zhao XX, Yuan QZ, Mu DP, Sun DW, Bo QA, Pan GZ, Li GQ, Cui T, Ding PP, You FP, Hao L, Wang MX, Zhang J Tags: Int J Clin Exp Pathol Source Type: research

MicroRNA-130a inhibits cell proliferation, invasion and migration in human breast cancer by targeting the RAB5A.
In this study, we found that the expression level of miR-130a was down-regulated in breast cancer tissues and cells. Overexpression of miR-130a was able to inhibit cell proliferation, invasion and migration in MCF7 and MDA-MB-435 cells. With the bioinformatics analysis, we further identified that RAB5A was a directly target of miR-130a, and its mRNA and protein level was negatively regulated by miR-130a. Immunohistochemistry verified RAB5A was upregulated in breast cancer tissues. Therefore, the data reported here demonstrate that miR-130a is an important tumor suppressor in breast cancer, and imply that miR-130a/RAB5A axi...
Source: Clinical Breast Cancer - March 13, 2015 Category: Cancer & Oncology Authors: Pan Y, Wang R, Zhang F, Chen Y, Lv Q, Long G, Yang K Tags: Int J Clin Exp Pathol Source Type: research

Diagnostic and prognostic potential of serum angiopoietin-2 expression in human breast cancer.
Abstract BACKGROUND: Accumulating evidence demonstrated a link of increased expression of Angiopoietin-2 (Ang-2) with invasive and metastatic phenotypes of various types of human cancers. However, until now, the serum level and its diagnostic and prognostic potential in breast cancer have not been investigated. METHODS: Enzyme-linked immunosorbent assays were used to measure the levels of Ang-2. Sensitivity, specificity and area under curve (AUC) for serum Ang-2 levels were determined using receiver operator characteristic (ROC) analysis. Survival curves were plotted using the Kaplan-Meier method and differen...
Source: Clinical Breast Cancer - March 13, 2015 Category: Cancer & Oncology Authors: Li P, He Q, Luo C, Qian L Tags: Int J Clin Exp Pathol Source Type: research

Elevated Aurora B expression contributes to chemoresistance and poor prognosis in breast cancer.
In this study, we conducted immunohistochemistry using antibodies against Aurora-B, S1981p-ATM, Ki67, and p53 in paraffin-embedded tumor tissues from 312 invasive breast cancer patients. The correlation between disease-free-survival (DFS) and Aurora-B expression was analyzed using the Kaplan-Meier method and log-rank test. A Cox proportional hazards regression analysis was used to determine whether Aurora-B was an independent prognostic factor for breast cancer. We found that Aurora-B expression was correlated with the proliferation index (P
Source: Clinical Breast Cancer - March 13, 2015 Category: Cancer & Oncology Authors: Zhang Y, Jiang C, Li H, Lv F, Li X, Qian X, Fu L, Xu B, Guo X Tags: Int J Clin Exp Pathol Source Type: research

Evaluation of biomarker changes after administration of various neoadjuvant chemotherapies in breast cancer.
Abstract To assess the changes in estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67 expression in breast cancer patients after various neoadjuvant chemotherapies. Data from 138 locally advanced breast cancer patients with histological diagnoses were reviewed. Seventy patients (group 1) were given 4 cycles of 500 mg/m(2) cyclophosphamide and 50 mg/m(2) pirarubicin every 21 days. Sixty-eight patients (group 2) were given 4 cycles of 500 mg/m(2) cyclophosphamide and 75 mg/m(2) docetaxel every 21 days. The biomarker changes of the operated tumor tissues were ...
Source: Clinical Breast Cancer - March 13, 2015 Category: Cancer & Oncology Authors: Jin G, Han Y, Liu C, Chen L, Ding B, Xuan S, Liu X, Ma G, Gao J, Tian X Tags: Int J Clin Exp Pathol Source Type: research

MUC1-mediated motility in breast cancer: a review highlighting the role of the MUC1/ICAM-1/Src signaling triad.
Abstract Breast cancer is the most common cancer in women with the leading cause of death being metastasis, the spread of cancer to distant organs. For those patients with high-risk estrogen receptor positive (ER+) breast cancer, an increased expression of the glycoprotein MUC1 is associated with resistance to anti-hormonal therapy, metastasis and death. Tumor cells may use MUC1 to metastasize by exploiting the vascular adhesion pathways used by leukocytes during the inflammatory response. MUC1 is a type 1 transmembrane protein whose cytoplasmic tail acts as a scaffold for several signaling pathways including the ...
Source: Clinical Breast Cancer - March 11, 2015 Category: Cancer & Oncology Authors: Haddon L, Hugh J Tags: Clin Exp Metastasis Source Type: research

Pituitary stalk thickening on MRI: When is the best time to re-scan and how long should we continue re-scanning for?
This article is protected by copyright. All rights reserved. PMID: 25759231 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 11, 2015 Category: Cancer & Oncology Authors: Di Iorgi N, Morana G, Maghnie M Tags: Clin Endocrinol (Oxf) Source Type: research

Clinical drug interaction profile of idelalisib in healthy subjects.
This study enrolled 24 healthy subjects and evaluated (1) the effect of idelalisib on the pharmacokinetics (PK) of digoxin, a P-gp probe substrate, rosuvastatin, a breast cancer resistance protein and OATP1B1/OATP1B3 substrate, and midazolam, a CYP3A substrate, and (2) the effect of a strong inducer, rifampin, on idelalisib PK. Upon treatment, the most common clinical adverse events (AEs) were headache and pyrexia. Grade 3 transaminase increases were observed in 5 of 24 subjects and were reversible. Two subjects had serious AEs after treatment completion (grade 3 pyrexia and/or drug-induced liver injury). Idelalisib coadmi...
Source: Clinical Breast Cancer - March 11, 2015 Category: Cancer & Oncology Authors: Jin F, Robeson M, Zhou H, Moyer C, Wilbert S, Murray B, Ramanathan S Tags: J Clin Pharmacol Source Type: research

Semi-mechanistic model to characterize non-linear pharmacokinetic of nimotuzumab in patients with advanced breast cancer.
This study aims i) to develop a semi-mechanistic pharmacokinetic (PK) model for nimotuzumab, in patients with advanced breast cancer ii) to identify demographic, biochemical and clinical predictive factors of the PK variability. Data from a phase I study were analyzed using the nonlinear mixed effects approach (NONMEM). A target-mediated disposition model that included two-open PK compartments, the mAb-target binding and target and mAb-target complex turnovers, described best the linear and non-linear PK. Covariates had no influence on the PK parameters. The final parameter estimates were 19.93 L (steady state volume), 0.0...
Source: Clinical Breast Cancer - March 11, 2015 Category: Cancer & Oncology Authors: Rodríguez-Vera L, Suzarte MR, Fernández-Sánchez E, Soriano JL, Peraire Guitart C, Castañeda Hernández G, Jacobo Cabral CO, de Castro Suárez N, Colom Codina H Tags: J Clin Pharmacol Source Type: research

Tumor-Infiltrating Lymphocytes in Breast Cancer: Ready for Prime Time?
A, Pandiella A, Amir E PMID: 25753437 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 9, 2015 Category: Cancer & Oncology Authors: Ocaña A, Diez-Gónzález L, Adrover E, Fernández-Aramburo A, Pandiella A, Amir E Tags: J Clin Oncol Source Type: research

Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: A Biomarker for Use Beyond Prognosis?
PMID: 25753438 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 9, 2015 Category: Cancer & Oncology Authors: Tsoutsou PG, Bourhis J, Coukos G Tags: J Clin Oncol Source Type: research

National Guidelines and Level of Evidence: Comments on Some of the New Recommendations in the American Society of Clinical Oncology and the College of American Pathologists Human Epidermal Growth Factor Receptor 2 Guidelines for Breast Cancer.
PMID: 25753440 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 9, 2015 Category: Cancer & Oncology Authors: Rakha EA, Pigera M, Shaaban A, Shin SJ, D'Alfonso T, Ellis IO, Lee AH Tags: J Clin Oncol Source Type: research

Reply to E.A. Rakha et al.
PMID: 25753441 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 9, 2015 Category: Cancer & Oncology Authors: Wolff AC, Hammond ME, Hicks DG, Allison KH, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Dowsett M, McShane LM, Hayes DF Tags: J Clin Oncol Source Type: research

Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
Conclusion: These data indicate no clinically relevant pharmacokinetic interaction between pradigastat and rosuvastatin. PMID: 25740267 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 5, 2015 Category: Cancer & Oncology Authors: Kulmatycki K, Hanna I, Meyers D, Salunke A, Movva A, Majumda T, Natrillo A, Vapurcuyan A, Rebello S, Sunkara G, Chen J Tags: Int J Clin Pharmacol Ther Source Type: research

Breast cancer: CLEOPATRA sheds light on how to tackle metastatic disease.
PMID: 25734635 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 3, 2015 Category: Cancer & Oncology Authors: Errico A Tags: Nat Rev Clin Oncol Source Type: research

Awareness of Breast Density and Its Impact on Breast Cancer Detection and Risk.
Abstract PURPOSE: Legislation mandating disclosure of breast density (BD) information has passed in 21 states; however, actual awareness of BD and knowledge of its impact on breast cancer detection and risk are unknown. METHODS: We conducted a national cross-sectional survey administered in English and Spanish using a probability-based sample of screening-age women, with oversampling of Connecticut, the only state with BD legislation in effect for> 1 year before the survey. RESULTS: Of 2,311 women surveyed, 65% responded. Overall, 58% of women had heard of BD, 49% knew that BD affects breast cancer de...
Source: Clinical Breast Cancer - March 2, 2015 Category: Cancer & Oncology Authors: Rhodes DJ, Radecki Breitkopf C, Ziegenfuss JY, Jenkins SM, Vachon CM Tags: J Clin Oncol Source Type: research

BGX-Ki-67 Index as a Supplementary Marker to MIB-1 Index, Enabling More Precise Distinction Between Luminal A and B Subtypes of Breast Carcinoma and Eliminating the Problem of Membranous/Cytoplasmic MIB-1 Staining.
CONCLUSIONS: In carcinomas with membranous/cytoplasmic MIB-1 staining, additional assessment of BGXLI is recommended. It may help in defining breast cancer subtype and in selection of individuals at risk who, despite appropriate therapy, would benefit from more frequent controls aimed at earlier implementation of second-line treatment. PMID: 25696801 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 21, 2015 Category: Cancer & Oncology Authors: Niemiec J, Adamczyk A, Ambicka A, Mucha-Małecka A, Wysocki WM, Majchrzyk K, Ryś J Tags: Am J Clin Pathol Source Type: research

Dual HER2 Gene Protein Assay: Focused Study of Breast Cancers With 2+ Immunohistochemical Expression.
CONCLUSIONS: Although GPA is an alternative to both IHC and FISH, it may be an unnecessary test for IHC 0/1+/3+ cases. The clinical utility of GPA appears to be similar to other in situ hybridization assays (ie, adjudicator of HER2 status for IHC 2+ cases). PMID: 25696805 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 21, 2015 Category: Cancer & Oncology Authors: Li Z, Dabbs DJ, Cooper KL, Bhargava R Tags: Am J Clin Pathol Source Type: research

Financial barriers to utilization of screening and treatment services for breast cancer: An equity analysis in Nigeria.
CONCLUSION: Financial barriers limit the ability of women, especially the poorest SES group, to utilize screening and treatment services for early diagnosis and treatment of breast cancer. Interventions that will improve financial risk protection for women with breast cancer or at risk of breast cancer are needed to ensure equitable access to screening and treatment services. PMID: 25666009 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 13, 2015 Category: Cancer & Oncology Authors: Okoronkwo IL, Ejike-Okoye P, Chinweuba AU, Nwaneri AC Tags: Niger J Clin Pract Source Type: research

Peripherally inserted central catheter thrombosis incidence and risk factors in cancer patients: a double-center prospective investigation.
CONCLUSIONS: The incidence of PICC thrombosis is relatively high, and nearly half are asymptomatic. Less activity and obesity are risk factors of PICC-related thrombosis. PMID: 25673995 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 13, 2015 Category: Cancer & Oncology Authors: Liu Y, Gao Y, Wei L, Chen W, Ma X, Song L Tags: Ther Clin Risk Manag Source Type: research

Zinc distribution within breast cancer tissue: A possible marker for histological grading?
CONCLUSIONS: Differentiation between carcinomatous tissue and stroma by determination of zinc content and the correlation of zinc concentration with the histological malignancy grade not only provides a key feature for clinical decision making for cancer therapy but also suggests the trace metal zinc as a potential biomarker for breast cancer. PMID: 25672953 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 12, 2015 Category: Cancer & Oncology Authors: Riesop D, Hirner AV, Rusch P, Bankfalvi A Tags: J Cancer Res Clin Oncol Source Type: research

Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer.
Abstract Sequential use of endocrine agents is common in estrogen receptor (ER)-positive metastatic breast cancer (MBC). In premenopausal women with MBC, tamoxifen and/or a luteinizing hormone-releasing hormone (LH-RH) agonist are options for endocrine treatment. Meta-analysis showed that the combination of the two agents is superior to either monotherapy. Under ovarian ablation or function-suppression, an agent used to treat postmenopausal women, such as the aromatase inhibitor (AI), fulvestrant, becomes possible as a subsequent therapy. In postmenopausal women, endocrine treatment options are widely available an...
Source: Clinical Breast Cancer - February 12, 2015 Category: Cancer & Oncology Authors: Iwase H, Yamamoto Y Tags: Int J Clin Oncol Source Type: research

Visual assessment of Ki67 using a 5-grade scale (Eye-5) is easy and practical to classify breast cancer subtypes with high reproducibility.
Abstract AIMS: Personalised breast cancer therapy requires pathological characterisation of tumours. The proliferative index, based on Ki67, is pivotal, but a standard method has not been established. Here we look for an easy and practical way to evaluate Ki67. METHODS: Immunohistochemical staining of estrogen receptors, progesterone receptors, HER2 and Ki67 (MIB-1) was performed on resected specimens from 406 primary invasive ductal carcinomas. Ki67 labelling index (LI) from manual counting was compared with visual assessment using a 5-grade scale (Eye-5). Next, 10 pathologists evaluated 100 samples with mar...
Source: Clinical Breast Cancer - February 11, 2015 Category: Cancer & Oncology Authors: Hida AI, Bando K, Sugita A, Maeda T, Ueda N, Matsukage S, Nakanishi M, Kito K, Miyazaki T, Ohtsuki Y, Oshiro Y, Inoue H, Kawaguchi H, Yamashita N, Aogi K, Moriya T Tags: J Clin Pathol Source Type: research

FDG and 82Rb PET/MRI Features of Brain Metastasis of Breast Cancer.
Abstract A 64-year-old female patient with stage IV breast cancer underwent an FDG and Rb PET brain studies. The PET brain images were fused with MRI brain T1 post-contrast images. The known enhancing left superoposterior frontal brain metastasis is positive on both FDG Rb PET/MRI images. The Rb PET/MRI showed better target-to-noise ratio, but showed nonspecific uptake in the superior sagittal sinus. PMID: 25674864 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 11, 2015 Category: Cancer & Oncology Authors: Lu Y Tags: Clin Nucl Med Source Type: research

Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients.
CONCLUSION: Based on data from our patient cohort of Japanese women with HER2-positive early-stage breast cancer, the efficacy and safety of systemic therapy with TZM are comparable to data from previously conducted large trials. Progress in anti-HER2 therapy for patients aged ≥70 years who have a poorer prognosis is needed. PMID: 25666483 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 10, 2015 Category: Cancer & Oncology Authors: Yamshiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Ohno S, Kuroi K, Takano T, Takada M, Yasuno S, Morita S, Toi M Tags: Int J Clin Oncol Source Type: research

Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor.
PMID: 25666484 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 10, 2015 Category: Cancer & Oncology Authors: Iwase H Tags: Int J Clin Oncol Source Type: research

Axillary lymph node management in breast cancer with positive sentinel lymph node biopsy.
Abstract The surgical treatment of localized breast cancer has become progressively less aggressive over the years. The management of the axillary lymph nodes has been modified by the introduction of sentinel lymph node biopsy. Axillary dissection can be avoided in patients with sentinel lymph node negative biopsies. Based on randomized trials data, it has been proposed that no lymph node dissection should be carried out even in certain patients with sentinel lymph node positive biopsies. This commentary discusses the basis of such recommendations and cautions against a general omission of lymph node dissection in...
Source: Clinical Breast Cancer - February 10, 2015 Category: Cancer & Oncology Authors: Voutsadakis IA, Spadafora S Tags: World J Clin Oncol Source Type: research

Management of locally advanced breast cancer-perspectives and future directions.
Abstract Locally advanced breast cancer (LABC) constitutes a heterogeneous entity that includes advanced-stage primary tumours, cancers with extensive nodal involvement and inflammatory breast carcinomas. Although the definition of LABC can be broadened to include some large operable breast tumours, we use this term to strictly refer to inoperable cancers that are included in the above-mentioned categories. The prognosis of such tumours is often unfavourable; despite aggressive treatment, many patients eventually develop distant metastases and die from the disease. Advances in systemic therapy, including radiation...
Source: Clinical Breast Cancer - February 10, 2015 Category: Cancer & Oncology Authors: Tryfonidis K, Senkus E, Cardoso MJ, Cardoso F Tags: Nat Rev Clin Oncol Source Type: research

Prognostic importance of ultrasound BI-RADS classification in breast cancer patients.
CONCLUSIONS: Breast Imaging Reporting and Data System classification might be considered as prognostic factors especially in Stage I breast cancer. Further confirmatory studies are needed. PMID: 25670765 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 10, 2015 Category: Cancer & Oncology Authors: Kim JY, Jung EJ, Park T, Jeong SH, Jeong CY, Ju YT, Lee YJ, Hong SC, Ha WS, Choi SK Tags: Jpn J Clin Oncol Source Type: research

There Are Two Prophylactic Human Papillomavirus Vaccines Against Cancer, and They Are Different.
PMID: 25667272 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 9, 2015 Category: Cancer & Oncology Authors: Tjalma WA Tags: J Clin Oncol Source Type: research

Beliefs about weight and breast cancer: an interview study with high risk women following a 12 month weight loss intervention.
CONCLUSION: Beliefs about weight and breast cancer risk were informed by social networks, media reports and personal experiences of significant others diagnosed with breast cancer. Our study has highlighted common doubts, anxieties and questions and the importance of providing a credible rationale for weight control and weight loss which addresses individual concerns. Counselling and health education material should be tailored to facilitate understanding of both genetic and modifiable risk factors and should do more help individuals to visualise the weight and breast cancer link. PMID: 25648828 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 6, 2015 Category: Cancer & Oncology Authors: Wright CE, Harvie M, Howell A, Evans DG, Hulbert-Williams N, Donnelly LS Tags: Hered Cancer Clin Pract Source Type: research

Endothelial follicle-stimulating hormone receptor expression in invasive breast cancer and vascular remodeling at tumor periphery.
Abstract BackgroundFollicle-stimulating hormone receptor (FSHR) is expressed on the endothelial surface of blood vessels associated with solid tumor periphery, where angiogenesis is known to occur. The correlation between FSHR expression and formation of new peritumoral vessels has not been previously investigated.MethodsWe used immunohistochemical techniques involving specific antibodies to detect FSHR and the endothelial markers (CD34, VEGFR2, and D2-40) in tissue samples from 83 patients with lymph node-negative, invasive breast cancer representing four main clinical treatment groups: HR+/HER2-, HR+/HER2+, HR-/...
Source: Clinical Breast Cancer - February 5, 2015 Category: Cancer & Oncology Authors: Planeix F, Siraj MA, Bidard FC, Robin B, Pichon C, Sastre-Garau X, Antoine M, Ghinea N Tags: J Exp Clin Cancer Res Source Type: research

Mechanisms of hormonal therapy resistance in breast cancer.
Abstract Whilst estrogen receptor (ER)-positive breast cancers are preferentially treated with hormone therapy, approximately one-third of them relapse. The mechanisms of refractoriness have been investigated by numerous studies but have not been fully clarified. Hormonal therapy resistance, particularly aromatase inhibitor (AI) resistance, may be related to the acquisition of alternative intracellular ER signaling. We have been investing the mechanisms using cancer specimens and cell lines by monitoring the transcription activity of ERs. AI refractory specimens showed diverse ER activity in the adenovirus estroge...
Source: Clinical Breast Cancer - February 5, 2015 Category: Cancer & Oncology Authors: Hayashi SI, Kimura M Tags: Int J Clin Oncol Source Type: research

Ras suppressor-1 promotes apoptosis in breast cancer cells by inhibiting PINCH-1 and activating p53-upregulated-modulator of apoptosis (PUMA); verification from metastatic breast cancer human samples.
Abstract Metastasis, responsible for most deaths from breast cancer (BC), is a multistep process leading to cancer cell spread. Extracellular matrix (ECM)-related adhesion and apoptosis resistance play pivotal role in metastasis. Ras suppressor-1 (RSU-1) localizes to cell-ECM adhesions and binds to pro-survival adhesion protein PINCH-1. Little is known about the role of RSU-1 in BC. In the present study, we investigated the role of RSU-1 in BC metastasis using two BC cell lines that differ in terms of their metastatic potential and a set of 32 human BC samples from patients with or without lymph node metastasis. W...
Source: Clinical Breast Cancer - February 3, 2015 Category: Cancer & Oncology Authors: Giotopoulou N, Valiakou V, Papanikolaou V, Dubos S, Athanassiou E, Tsezou A, Zacharia LC, Gkretsi V Tags: Clin Exp Metastasis Source Type: research

Expression distribution of cancer stem cells, epithelial to mesenchymal transition, and telomerase activity in breast cancer and their association with clinicopathologic characteristics.
Abstract A total of 167 surgically resected primary invasive breast carcinomas and 63 metastatic lymph node lesions were analyzed for immunohistochemical (IHC) localization of the CD44(+)CD24(-low) breast cancer stem cell (CSC) markers, epithelial to mesenchymal transition (EMT) markers, and telomerase activity by double-staining IHC technique, in formalin-fixed, paraffin-embedded tissue, the results were validated by double-staining immunofluorescent and flow cytometry techniques. The results showed that CSCs with CD44(+)CD24(-low) phenotype were significantly increased in node-positive tumors, high-grade tumors,...
Source: Clinical Breast Cancer - February 2, 2015 Category: Cancer & Oncology Authors: Makki J, Myint O, Wynn AA, Samsudin AT, John DV Tags: Clin Med Insights Pathol Source Type: research

Identification of a new BRCA2 large genomic deletion associated with high risk male breast cancer.
CONCLUSION: Large rearrangements in BRCA1 and BRCA2 occur in a small percentage (
Source: Clinical Breast Cancer - February 2, 2015 Category: Cancer & Oncology Authors: Timoteo AR, Albuquerque BM, Moura PC, Ramos CC, Agnez-Lima LF, Walsh T, King MC, Lajus TB Tags: Hered Cancer Clin Pract Source Type: research

HER2 and β-catenin protein location: importance in the prognosis of breast cancer patients and their correlation when breast cancer cells suffer stressful situations.
In conclusion, this study shows the dynamical associations of HER2 and β-catenin and their changes in subcellular localizations driven by stressful situations. In addition, we report for the first time the correlation between plasma membrane associated β-catenin in HER2-positive breast cancer and survival outcome, and the importance of the protein localization in breast cancer samples. PMID: 25636904 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 1, 2015 Category: Cancer & Oncology Authors: Cuello-Carrión FD, Shortrede JE, Alvarez-Olmedo D, Cayado-Gutiérrez N, Castro GN, Zoppino FC, Guerrero M, Martinis E, Wuilloud R, Gómez NN, Biaggio V, Orozco J, Gago FE, Ciocca LA, Fanelli MA, Ciocca DR Tags: Clin Exp Metastasis Source Type: research

[(18)F]Fluorodeoxyglucose PET/Computed Tomography in Breast Cancer and Gynecologic Cancers: A Literature Review.
en PT Abstract In this literature review, an update is provided on the role of [(18)F]fluorodeoxyglucose PET/computed tomography in different clinical settings of the 4 most frequent female-specific cancer types: breast, endometrial, ovarian, and cervical cancer. The most recent knowledge regarding primary diagnosis, staging, response evaluation, prognostic and predictive values, recurrence detection, and radiotherapy planning is evaluated, including, when clinically relevant, considerations with respect to the epidemiology, treatment, and course of the diseases. PMID: 25455882 [PubMed - as supplied by publis...
Source: Clinical Breast Cancer - December 7, 2014 Category: Cancer & Oncology Authors: Hildebrandt MG, Kodahl AR, Teilmann-Jørgensen D, Mogensen O, Jensen PT Tags: PET Clin Source Type: research

Effect of Paullinia cupana on MCF-7 breast cancer cell response to chemotherapeutic drugs.
DA Cruz IB Abstract Previous studies suggested that certain plants, such as guarana (Paullinia cupana), exert a protective effect against cancer-related fatigue in breast cancer patients undergoing chemotherapy. However, guarana possesses bioactive molecules, such as caffeine and catechin, which may affect the pharmacological properties of antitumor drugs. Therefore, the aim of this study was to evaluate the effects of guarana on breast cancer cell response to 7 chemotherapeutic agents currently used in the treatment of breast cancer. To perform this study, MCF-7 breast cancer cells were cultured under controlled ...
Source: Clinical Breast Cancer - December 7, 2014 Category: Cancer & Oncology Authors: Hertz E, Cadoná FC, Machado AK, Azzolin V, Holmrich S, Assmann C, Ledur P, Ribeiro EE, DE Souza Filho OC, Mânica-Cattani MF, DA Cruz IB Tags: Mol Clin Oncol Source Type: research

Assessment of health-related quality of life of patients with esophageal squamous cell carcinoma following esophagectomy using EORTC quality of life questionnaires.
Abstract Esophageal cancer is one of the leading causes of cancer-related mortality and surgery is currently the main treatment modality for resectable esophageal cancer. To assess health-related quality of life (HRQL) of patients with esophageal squamous cell carcinoma (ESCC) following esophagectomy, 62 consecutive patients with middle ESCC were randomly assigned into hand video-assisted thoracoscopic surgery (HVATS) (n=33) and Ivor-Lewis surgery (ILS) (n=29) groups. Quality of life questionnaires (QLQ)-C30 and QLQ-OES18, published by the European Organization for Research and Treatment of Cancer, were used prior...
Source: Clinical Breast Cancer - December 7, 2014 Category: Cancer & Oncology Authors: Shen O, Wang J, Li W, Yi W, Wang W Tags: Mol Clin Oncol Source Type: research

Potential risk factors for the development of seroma following mastectomy with axillary dissection.
In conclusion, the prediction of the development of seroma following mastectomy with axillary dissection is challenging. However, a longer operative time and the non-use of PCA may represent potential risk factors for this complication. PMID: 25469299 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - December 7, 2014 Category: Cancer & Oncology Authors: Pan XF, Huan JL, Qin XJ Tags: Mol Clin Oncol Source Type: research

Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer.
The objective of this study was to investigate the association of serum cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) levels with clinicopathological parameters in patients diagnosed with metastatic breast cancer (MBC). We retrospectively evaluated the medical records of 284 patients diagnosed with MBC between January, 2007 and December, 2012 who fulfilled the specified criteria and the association between the levels of the two tumor marker and clinicopathological parameters was analyzed. Of the 284 patients, elevated CA 15-3 and CEA levels at initial diagnosis of recurrence were identified in 163 (57.4%...
Source: Clinical Breast Cancer - December 7, 2014 Category: Cancer & Oncology Authors: Geng B, Liang MM, Ye XB, Zhao WY Tags: Mol Clin Oncol Source Type: research